“Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients With Active Psoriatic Arthritis: Results from a Phase 2 Trial”. SKIN The Journal of Cutaneous Medicine 8, no. 2 (March 18, 2024): s383. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/2678.